Lexicon Pharmaceuticals | LXRX - Les Charges D'Exploitation





Les Charges D'Exploitation Changement Date
Abbott USD 10.46B 1.15B 2026-06
Acadia Pharmaceuticals USD 270.12M 2.55M 2026-06
Agios Pharmaceuticals USD 130.77M 10.77M 2026-03
Akebia Therapeutics USD 63.08M 8.26M 2025-12
Alnylam Pharmaceuticals USD 1.06B 160.97M 2026-06
AstraZeneca USD 12.22B 4.04B 2026-06
BioMarin Pharmaceutical USD 6.32B 5.69B 2026-06
Coherus Biosciences USD 51.83M 2.48M 2025-12
Eli Lilly USD 10.52B 496M 2026-06
Halozyme Therapeutics USD 193.34M 1.15M 2026-06
Illumina USD 899M 47M 2026-06
Insmed USD 526.79M 20.55M 2026-06
Ironwood Pharmaceuticals USD 57.33M 8.63M 2024-12
J&J USD 18.93B 1.09B 2026-09
Lexicon Pharmaceuticals USD 20.27M 6.1M 2025-12
MacroGenics USD 42.87M 21.68M 2026-06
MannKind USD 110.21M 690K 2026-06
Merck USD 15.77B 2.4B 2026-06
Moderna USD 960M 817M 2026-06
Novartis USD 10.2B 912M 2026-06
PTC Therapeutics USD 226.66M 19.64M 2026-03
Puma Biotechnology USD 49.26M 3.2M 2024-06
Sarepta Therapeutics USD 387.96M 15.59M 2026-06
Thermo Fisher Scientific USD 9.81B 716M 2026-06
Ultragenyx Pharmaceutical USD 289M 16M 2026-06
United Therapeutics USD 6.4B 499.2M 2026-06
Vanda Pharmaceuticals USD -1.14B 1.6B 2025-12